Advertisement

Topics

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Company Profile

21:15 EDT 18th June 2018 | BioPortfolio


News Articles [2209 Associated News Articles listed on BioPortfolio]

M&As this week: Novartis, Roche, Alexion

Swiss healthcare solutions provider Novartis has agreed to purchase AveXis for $8.7bn. Novartis has formed a subsidiary named Novartis Merger...Read More... The post M&As this week: Novartis, Roc...

Novartis:FDA Approves Lutathera For Gastroenteropancreatic Neuroendocrine Tumors

BASEL (dpa-AFX) - Novartis AG (NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new d...

Novartis Closes Tender Offer For Advanced Accelerator Applications

BASEL (dpa-AFX) - Novartis AG (NVS) announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A., to buy all of the outstanding ordinary shares, including...

BridgeBio picks up shelved Novartis drug, kicks off new subsidiary

New BridgeBio subsidiary QED Therapeutics will develop Novartis' infigratinib in more than cancer.

Novartis Completes Acquisition Of AveXis

BASEL (dpa-AFX) - Novartis AG (NVS) said that it has completed the acquisition of AveXis, Inc. through the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger Corp...

Novartis completes $8.7bn acquisition of AveXis

Novartis has completed its $8.7bn acquisition of US-based clinical stage gene therapy company AveXis via the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger with a...

Open resources at Novartis help drive innovation

“Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible,” says Bernardo Bazet Lyonnet, a postdoctoral researcher who fir...

Report: Novartis Could Put Sandoz on the Auction Block Within a Few Weeks

Novartis may soon be looking to sell off its generics subsidiary Sandoz.

PubMed Articles [143 Associated PubMed Articles listed on BioPortfolio]

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine.

When faced with a diagnosis of multiple sclerosis (MS), patients often turn to the Internet and social media to find support groups, read about the experiences of other people affected by MS and seek ...

The intracellular and intercellular cross-talk during subsidiary cell formation in Zea mays: existing and novel components orchestrating cell polarization and asymmetric division.

Formation of stomatal complexes in Poaceae is the outcome of three asymmetric and one symmetric cell division occurring in particular leaf protodermal cells. In this definite sequence of cell division...

How Often Do Safety Signals Occur by Chance in First-in-Human Trials?

Clinicians working on first-in-human clinical studies need to be able to judge whether safety signals observed on an investigational drug were more likely to have occurred by chance or to have been ca...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

Continuous manufacturing of co-crystals: challenges and prospects.

The last decade has witnessed extensive growth in the field of co-crystallization for mitigating the solubility and dissolution-related issues of poorly soluble drugs. This is largely because co-cryst...

Clinical Trials [298 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive f...

Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition

The purpose of this study is to compare the single-dose oral bioavailability of oxcarbazepine 300 mg/5mL oral suspension of OHM Laboratories, USA (a subsidiary of Ranbaxy Pharmaceuticals I...

Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions

The study was conducted as an open label, balanced, randomized, two-treatment, two-period, two-sequence, single- dose, crossover bioavailability study comparing oxcarbazepine 300 mg/5mL or...

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines

This study will evaluate the safety, tolerability and immunogenicity of one or two 0.25mL or 0.5mL intramuscular injections of influenza vaccine compared with control vaccine in subjects 6...

Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study

The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, ...

Companies [2376 Associated Companies listed on BioPortfolio]

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG

Novartis Consumer Health

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innova...

Novartis AG

Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the...

Novartis Vaccines and Diagnostics

Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. Through industry-leading scientific expertise, the company is focused on extending critical ...

Idenix Pharmaceuticals

Idenix is pursuing a disciplined business strategy that seeks to capitalize upon the diverse expertise of the company’s management team. While Idenix is focused on bringing its late-stage product ca...

More Information about "Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG" on BioPortfolio

We have published hundreds of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG news stories on BioPortfolio along with dozens of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Clinical Trials and PubMed Articles about Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Companies in our database. You can also find out about relevant Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record